06:35 AM EDT, 09/18/2024 (MT Newswires) -- Promino Nutritional Sciences ( MUSLF ) on Wednesday announced the launch of the preclinical trial to test the effectiveness of Promino's patented essential amino acid blend for the retention of muscle mass in cancer patients undergoing aggressive chemotherapy treatment.

The preclinical trial will be led by Dr. Patrick Gunning, who was appointed as special advisor to the company, to conduct these trials.

Results of the trials are expected in 10 weeks. If testing affirms the effectiveness of the amino acid blend in retaining muscle mass in chemotherapy patients, the company will likely develop a specialized formula specifically for marketing to the practitioner channel in North America.